JPWO2020223435A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020223435A5 JPWO2020223435A5 JP2021564373A JP2021564373A JPWO2020223435A5 JP WO2020223435 A5 JPWO2020223435 A5 JP WO2020223435A5 JP 2021564373 A JP2021564373 A JP 2021564373A JP 2021564373 A JP2021564373 A JP 2021564373A JP WO2020223435 A5 JPWO2020223435 A5 JP WO2020223435A5
- Authority
- JP
- Japan
- Prior art keywords
- rsv
- pharmaceutical composition
- monoclonal antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840701P | 2019-04-30 | 2019-04-30 | |
| US62/840,701 | 2019-04-30 | ||
| PCT/US2020/030619 WO2020223435A1 (en) | 2019-04-30 | 2020-04-30 | Dosage regimens for and compositions including anti-rsv antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022531205A JP2022531205A (ja) | 2022-07-06 |
| JPWO2020223435A5 true JPWO2020223435A5 (he) | 2023-05-11 |
Family
ID=70779897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564373A Pending JP2022531205A (ja) | 2019-04-30 | 2020-04-30 | 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220204593A1 (he) |
| EP (1) | EP3962940A1 (he) |
| JP (1) | JP2022531205A (he) |
| KR (1) | KR20220002427A (he) |
| CN (1) | CN113825767A (he) |
| AU (1) | AU2020265676A1 (he) |
| BR (1) | BR112021020846A2 (he) |
| CA (1) | CA3138180A1 (he) |
| CO (1) | CO2021014370A2 (he) |
| EA (1) | EA202192776A1 (he) |
| IL (1) | IL287443A (he) |
| MX (1) | MX2021013248A (he) |
| SG (1) | SG11202111748TA (he) |
| TW (1) | TW202106333A (he) |
| WO (1) | WO2020223435A1 (he) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008921B1 (fr) | 2013-07-23 | 2015-12-25 | Safran | Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece |
| CA3235178A1 (en) * | 2017-03-01 | 2018-09-07 | Medimmmune Limited | Formulations of monoclonal antibodies |
| TWI761453B (zh) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
-
2020
- 2020-04-30 TW TW109114519A patent/TW202106333A/zh unknown
- 2020-04-30 WO PCT/US2020/030619 patent/WO2020223435A1/en unknown
- 2020-04-30 JP JP2021564373A patent/JP2022531205A/ja active Pending
- 2020-04-30 AU AU2020265676A patent/AU2020265676A1/en active Pending
- 2020-04-30 US US17/606,614 patent/US20220204593A1/en active Pending
- 2020-04-30 KR KR1020217038129A patent/KR20220002427A/ko unknown
- 2020-04-30 EA EA202192776A patent/EA202192776A1/ru unknown
- 2020-04-30 SG SG11202111748TA patent/SG11202111748TA/en unknown
- 2020-04-30 CA CA3138180A patent/CA3138180A1/en active Pending
- 2020-04-30 MX MX2021013248A patent/MX2021013248A/es unknown
- 2020-04-30 EP EP20727466.3A patent/EP3962940A1/en active Pending
- 2020-04-30 CN CN202080032470.XA patent/CN113825767A/zh active Pending
- 2020-04-30 BR BR112021020846A patent/BR112021020846A2/pt unknown
-
2021
- 2021-10-20 IL IL287443A patent/IL287443A/he unknown
- 2021-10-26 CO CONC2021/0014370A patent/CO2021014370A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130108636A1 (en) | High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins | |
| JPWO2021183359A5 (he) | ||
| US20210371503A1 (en) | Neutralizing antibodies against sars-related coronavirus | |
| AU2014306956A1 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| TW200912003A (en) | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | |
| CN115666649A (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| WO2017059813A1 (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| US20230227555A1 (en) | Cd-3 antibodies for the treatment of coronavirus | |
| JP2003531866A (ja) | 抗体を用いた呼吸器疾患の組合せ治療法 | |
| EP4135837A1 (en) | Methods for treating a complement mediated disorder caused by viruses | |
| JPWO2020223435A5 (he) | ||
| US20230227539A1 (en) | Methods and compositions related to neutralizing antibodies against human coronavirus | |
| US20230020548A1 (en) | Anti-interleukin 1 beta antibodies for treatment of sickle cell disease | |
| JPWO2020136101A5 (he) | ||
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| JPWO2021247779A5 (he) | ||
| US20200347120A1 (en) | Dosage regimens for and compositions including anti-rsv antibodies | |
| WO2021005232A1 (en) | Intranasal administration of neutralising antiviral antibodies | |
| WO2024102674A1 (en) | Antigen binding molecules targeting sars-cov-2 | |
| JP2023518815A (ja) | Ｉｌ６アンタゴニストによるｃｏｖｉｄ－１９肺炎を含む肺炎の治療方法 | |
| JP2024500322A (ja) | 併用療法 | |
| WO2024146630A1 (zh) | 一种tslp抗体治疗哮喘的方法 | |
| JP2023518812A (ja) | Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ | |
| JPWO2019147867A5 (he) | ||
| CN115531531A (zh) | 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途 |